Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 121.50 120.00 123.00 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -17.2 -45.2 - 39

Reneuron Share Discussion Threads

Showing 7726 to 7749 of 7750 messages
Chat Pages: 310  309  308  307  306  305  304  303  302  301  300  299  Older
DateSubjectAuthorDiscuss
12/12/2019
12:55
Well, so much for charts. Today we are down to a new low post the Woodford fiasco, and it seems that very little volume is needed to knock the share price. It looks like we may have to suffer more weakness until the overhang of Woodford's holding is redistributed. This, apparently, will be no earlier than the end of January. The Chairman (80,000 bought at 225p) must be feeling even sicker than I am.
dickbush
11/12/2019
12:53
Recent interview on YouTube https://www.youtube.com/watch?v=sROQ-Ubn4sA
dickbush
09/12/2019
10:43
last week's interims from reported the pleasing combination of encouraging early trial reports, a healthy cash balance (£21.3m at y/e), and the tie-up with leading Chinese player Fosun Pharma. New research note from Equity Development out and freely accessible here: https://www.equitydevelopment.co.uk/edreader/?ltkn=[ID]&d=%3D%3DwM2YjM
edmonda
09/12/2019
09:13
Thanks, Skipper. Interesting list of shareholders. Walker Crips? It's not a typo.
dickbush
08/12/2019
23:20
According to the FT tearsheets Woodford was down to 16.58% by 15th October. LFS was up to 16.42% by the same date. https://markets.ft.com/data/equities/tearsheet/profile?s=RENE:LSE
the skipper
08/12/2019
16:36
Just quoting IC. At the bottom of the table, it says: "Source companies Capital IQ, Investigate, Bloomberg, accurate as at 21 Nov 2019". Note, also, that the RENE shares did not go to Blackrock.
hashertu
08/12/2019
16:25
I'm open to correction but after selling a bit I understood his funds were down to a total of circa 33%. He was given a special dispensation to go to circa 35% through the issue at £5 in 2015. Is it really over four years ago that this was £6?.
dickbush
08/12/2019
10:50
Abstracted from Friday IC Woodford/Link Fund Solution shareholding in RENE 31/5/19 WIM 35.4% 21/11/19 LFS 16.4% The difference has been sold. Some way to go, unfortunately.
hashertu
06/12/2019
11:27
I'm no chartist but after going sideways to slightly up since October, the price has now moved above the 50 day weighted moving average. The unweighted 50 day moving average is circa 144p. With no news coming that is likely to be bad, and a couple of significant positives (a deal, Woodford's holding) in the offing, I've added this morning.
dickbush
06/12/2019
10:59
Looks like a triple bottom chartwise
volsung
06/12/2019
10:42
From the webcast: Following a protocol amendment next year a further 6 to 12 patients will be added to the RPC trial. Hoping to move straight to a phase 3 trial after results of the 2a trial. Patients would have both eyes treated and the control group would have no treatment. To avoid surgical related incidents, patients with very poor retinas unlikely to be treated. Moving to 2/3rds of patients being treated in the stroke trials. They were losing patients from the trial because the 50:50 odds were deemed too low.
dickbush
06/12/2019
09:09
Napoleon 14th. The cash burn of £5.15 mil was for one half, a period when they received a net £5.4 mil from Fosun. Without another Fosun payment they would have zero cash by September 30th 2020 and that's not even taking into account the major increase in spending required for a much greater number of patients in the CTX trial. The company needs money, probably a lot of it. The guy who was hired some six months ago to do Fosun-like deals needs to start earning his salary. With a deal or deals the share price should appreciate mightily, particularly once Woodford's shares are distributed. But the higher they go, the more certain is a placing or rights issue IMO.
dickbush
06/12/2019
08:37
"In the months ahead" is rather open-ended though. Anyone could interpret that to mean years ahead as months lead to years. Will hold and possibly top-up on any major weakness, but in hindsight should have sold in the 300p area and bought back. If only I was a trader!
lauders
06/12/2019
08:26
The best part for me was "We hope to be able to announce further deals with commercial third parties across our various programmes in the months ahead." They must be reasonably confident in this to state a time frame. Any further deals will provide a real confidence boost in the products and the progress they are making.
stevedd
06/12/2019
08:24
Looks OK. Cash = £21.3M, 2019 cashburn = £5.15M, so basically we have 4 years before needing funds, in the absence of any further progress in financial performance. Progress depends on scientific performance and saleability, about which I can only take the experts' words as I know nothing, like Manuel... Needs to get the Woodford factor done and dusted. I'll keep what shares I have here, reduced to a free carry. Might even add some if the chart looks positive.
napoleon 14th
06/12/2019
08:23
Perhaps we will now see the share price move back to more sensible levels.
bonzo
06/12/2019
08:15
Bought back in at 137p
volsung
06/12/2019
07:40
Rns reads well, all going well it seems
ayl30
29/11/2019
11:00
I'm no chartist but this has rallied up to its 50 day weighted moving average. Some speculation re the statement in a week's time or the reducing time to the resolution of the share overhang? Or just a nod to what has happened to IMM.
dickbush
28/11/2019
16:23
I see that Immupharma is up 325% on a US deal. The product has already done a Phase III trial with results a long way short of perfect. Now moving to a Phase III trial using patients who are much more likely to benefit. Sounds familiar.
dickbush
28/11/2019
10:03
Yes, this time next year Rodney.
small crow
28/11/2019
00:04
Stay positive - Those who know the technology are ...There's much more to come.
alimo
26/11/2019
10:35
Re Woodford Equity Income Fund. "BlackRock has been tasked with selling down the bulk of the fund's quoted stocks while PJT Park Hill will offload unquoted companies and selected listed but hard-to-trade small companies, ahead of a first distribution to investors expected in January." Rene was over £3 when Woodford's problems became public. Even taking into account the poorer than expected results from the RP update, we should see a much higher price once Woodford's Funds' holding is sold. The problem for the share price is getting from here to there. I hope to see a resolution by end-January 2020. I don't expect the results in ten days time to make much difference unless they have news on a Fosun-like deal. It's about time the guy who was hired to make such deals started to earn his salary.
dickbush
25/11/2019
21:50
Thank u for your fed back
hadley 1
Chat Pages: 310  309  308  307  306  305  304  303  302  301  300  299  Older
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191216 07:07:06